download Full Article (PDF file) - Journal of Gastrointestinal and ...

22
for development of the irritable bowel syndrome: postal survey of
patients. BMJ 1997; 314: 779–782.
4. Quigley EM. Irritable bowel syndrome and inflammatory bowel
disease: interrelated diseases? Chin J Dig Dis 2005; 6: 122-132.
5. Quigley EM. Disturbances of motility and visceral hypersensitivity
in irritable bowel syndrome: biological markers or epiphenomenon.
Gastroenterol Clin North Am 2005;34:221-233.
6. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in
patients with irritable bowel syndrome: sensitivity, specificity, and
predictive values of pain sensory thresholds. Gastroenterology 2002;
122: 1771-1777.
7. Lembo T, Munakata J, Mertz H, et al. Evidence for the
hypersensitivity of lumbar splanchnic afferents in irritable bowel
syndrome. Gastroenterology 1994; 107: 1686–1696.
8. Sheptulin AA. Modern notions on irritable bowel syndrome. Russian
Med Magazine 2001; 9: 538-542.
9. Thompson WG, Longstreth GF, Drossman D A, Heaton KW, Irvine
EJ, Muller-Lissner SA. Functional bowel disorders and functional
abdominal pain.. Gut 1999; 45 (Suppl 2): II43-47.
10. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin
F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;
130: 1480-1491.
11. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid
distension in irritable bowel syndrome. Gastroenterology 1990; 98:
1187–1192.
12. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal
perception is a biological marker of patients with irritable bowel
syndrome. Gastroenterology 1995; 109: 40-52.
13. Whitehead WE, Crowell MD, Davidoff AL, Palsson OS, Schuster
MM. Pain from rectal distension in women with irritable bowel
syndrome. Dig Dis Sci 1997; 42: 796–804.
14. Gershon MD. Importance of serotonergic mechanisms in
Khalif et al
gastrointestinal motility and sensation. In: Camilleri M, Spiller RC,
eds. Irritable bowel syndrome; diagnosis and treatment. Philadelphia,
WB Saunders Co. 2002, pp.95-116.
15. Mertz H. Altered CNS processing of visceral pain in IBS. In:
Camilleri M and Spiller RC eds. Irritable bowel syndrome; diagnosis
and treatment. Philadelphia WB Saunders Co 2002, pp.55-68.
16. Bharucha AE, Camilleri M, Haydock S, et al. Effects of a serotonin
5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor
and sensory function in humans. Gut 2000; 47: 667-674.
17. Baranskaya EK. Abdominal pain: clinical approach to a patient and
algorithm of the treatment. Pharmateca 2005; 14: 49-57.
18. Podmarenkova LF. Pathways of development of motor and
cumulative functions of the rectum in normal and when the sphincter
apparatus is disturbed. PhD Thesis, University of Moscow, 2000.
19. Mueller-Lissner S, Tytgat GN, et al. Placebo- and paracetamolcontrolled
study on the efficacy and tolerability of hyoscine
butylbromide in the treatment of patients with recurrent crampy
abdominal pain. Aliment Pharmacol Ther 2006; 23: 1741-1748.
20. Gupta B, Nellore V, Mittal S. Drotaverine hydrochloride versus
hyoscine-N-butylbromide in augmentation of labor. Int J Gynaecol
Obstet 2008; 100: 244-247.
21. Naliboff BD, Munakata J, Fullerton S, et al. Evidence for two distinct
perceptual alterations in irritable bowel syndrome. Gut 1997; 41:
505-512.
22. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral
perception in patients with pain-predominant irritable bowel
syndrome. Am J Gastroenterol 1999; 94: 1320–1326.
23. Delvaux М. Do we need to perform rectal distention tests to diagnose
IBS in clinical practice? Gastroenterology 2002; 122: 2075-2078.
24. Tytgat GN. Hyoscine butylbromide: a review of its use in the
treatment of abdominal cramping and pain. Drugs 2007; 67: 1343-
1357.